Abstract
Cardiovascular diseases and metabolic disorders are the most common groups of
disease in Eastern Europe. Moreover, poor housing standards have exacerbated
the spread of communicable diseases such as tuberculosis, diphtheria and
cholera. In Eastern European countries, the rising expenditure on prescription
pharmaceuticals is the leading contributor to increasing pressure on
healthcare finances, and has therefore been a major catalyst for healthcare
reforms. The Eastern European Pharmaceutical Market Outlook to 2014 provides a
comprehensive coverage of the Eastern European pharmaceutical market,
reviewing the market structure, pricing and regulation and includes detailed
epidemiological analyses of the common indications. This report makes a
wide-ranging assessment of the marketed product portfolio, R&D pipeline,
market share data, sales forecast and competitive landscape for the major
players in Eastern European market.
Table of Contents
Executive Summary
- The Eastern European healthcare environment
- Healthcare systems in Eastern Europe
- Therapeutic market analysis
- Leading players in Eastern Europe
Scope and methodology
Chapter 1 The Eastern European healthcare environment
- Summary
- Introduction
- Population profile
- Disease burden
- Macroeconomic comparison of Eastern European countries
- Economic landscape
- Healthcare spending
- Pharmaceutical sales growth
- Structural challenges to pharmaceutical marketers in Eastern Europe
- Key events
- Decentralization of the healthcare system leads to reduced expenditure
- Lack of funding in the Czech Republic leads to lack of innovation
- Implementation of cost-effectiveness improvement measures
- Strong performance of generic drug manufacturers
- Payers' acceptance of biosimilars will drive their uptake
Chapter 2 Healthcare systems in Eastern Europe
- Summary
- Introduction
- Profiles of healthcare systems across Eastern Europe
- Russia
- Healthcare system
- Pricing and reimbursement
- Political and regulatory status
- Ukraine
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Poland
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Romania
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- The Czech Republic
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Hungary
- Healthcare system
- Pricing and reimbursement
- Political and regulatory climate
- Slovakia
- Healthcare system
- Pricing and reimbursement
- Regulatory status
- Slovenia
- Healthcare system
- Pricing and reimbursement
- Regulatory status
Chapter 3 Therapeutic market analysis in Eastern Europe
- Summary
- Pharmaceutical market overview
- Therapy area analysis
- Therapy area sales forecast
- Therapy area analysis by country
- Poland
- Russia
- Hungary
- Romania
- The Czech Republic
- Ukraine
- Slovakia
- Slovenia
- Leading brands
- Lovenox
- Coversyl
- Glivec
- Vastarel
- NeoRecormon
- Daflon
- Plavix
- Fraxiparine
- Augmentin
- Seretide
- Leading brands sales forecast
- Key brand analysis by country
- Poland
- Coversyl and Triatec
- Fraxiparine
- Zolafren
- Singulair
- Russia
- Actovegin, Merrem and Arbidol
- Essentiale
- Viagra
- Theraflu
- No Spa
- Hungary
- Romania
- Pegasys
- Vastarel
- Zyprexa
- Augmentin
- Coversyl
- Coversyl
- The Czech Republic
- Seretide
- Symbicort
- Remicade
- Ukraine
- Essentiale
- Actovegin
- Mezym forte
- Mucosolvan
- Traumel S
- Slovakia
- Erypo
- Optinate
- Mabthera
- Slovenia
- Zyprexa
- Ultop, Atoris and Vasilip
- Fosamax plus D
Chapter 4 Leading players in Eastern Europe
- Summary
- Introduction
- Leading players
- Analysis of key players in the Eastern Europe
- Novartis
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Novartis' s pipeline focus
- Strategic growth analysis
- Sanofi-Aventis
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Sanofi-Aventis' s pipeline focus
- Strategic growth analysis
- GSK
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- GSK' s pipeline focus
- Strategic growth analysis
- Servier
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Servier' s pipeline focus
- Strategic growth analysis
- Roche
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Roche' s pipeline focus
- Strategic growth analysis
- Key regional player in Eastern Europe
- Zentiva
- Overview
- Sales focus by leading drug classes
- Marketed product portfolio
- Zentiva' s pipeline focus
- Strategic growth analysis
- Leading players sales forecast
Leading players analysis by country
- Poland
- Russia
- Hungary
- Romania
- The Czech Republic
- Ukraine
- Slovakia
- Slovenia
Chapter 5 Appendix
- Anatomical Therapeutic Classification (ATC)
- A: Alimentary tract and metabolism
- B: Blood and blood-forming organs
- C: Cardiovascular system
- D: Dermatologicals
- G: Genito-urinary system and sex hormones
- H: Systemic hormonal preparations
- J: General anti-infectives systemic
- L: Antineoplastic and immunomodulating agents
- M: Musculo-skeletal system
- N: Nervous system
- R: Respiratory system
- S: Sensory organs
- T: Diagnostic agents
- V: Various
- Licensing status as per IMS Health
- Original brand
- Other brand
- Licensed brand
- Patent N/A brands
- Unbranded/generic product
- Glossary
- Index
List of Figures
- Figure 1.1: Czech Republic GDP distribution across different sectors, 2007
- Figure 1.2: Comparison of healthcare expenditure across Eastern European
countries
- Figure 1.3: GDP growth vs. pharmaceutical sales growth, 2006 - 07
- Figure 1.4: Structural challenges shaping Eastern European market
development
- Figure 2.5: Financing of healthcare system in Poland 53
- Figure 3.6: Eastern European pharmaceutical market share by countries, 2007
- Figure 3.7: Eastern European pharmaceutical sales by therapy area, 2007
($m)
- Figure 3.8: Top 10 sub-therapy area sales in the Polish pharmaceutical
market, 2007 ($m)
- Figure 3.9: Top 10 sub-therapy area sales in the Russian pharmaceutical
market, 2007 ($m)
- Figure 3.10: Top 10 sub-therapy area sales in the Hungarian pharmaceutical
market, 2007 ($m)
- Figure 3.11: Top 10 sub-therapy area sales in the Romanian pharmaceutical
market, 2007 ($m)
- Figure 3.12: Top 10 sub-therapy area sales in the Czech Republican
pharmaceutical market, 2007 ($m)
- Figure 3.13: Top 10 sub-therapy area sales in the Ukrainian pharmaceutical
market, 2007 ($m)
- Figure 3.14: Top 10 sub-therapy area sales in the Slovakian pharmaceutical
market, 2007 ($m)
- Figure 3.15: Top 10 sub-therapy area sales in the Slovenian pharmaceutical
market, 2007 ($m)
- Figure 4.16: Market share of top 10 and other companies in the Eastern
European market, 2007
- Figure 4.17: Novartis' s Eastern European market sales by therapy area, 2007
- Figure 4.18: Novartis' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.19: Sanofi-Aventis' s Eastern European market sales by therapy
area, 2007
- Figure 4.20: Sanofi-Aventis' s leading brand sales break-up across the
Eastern European countries, 2007
- Figure 4.21: GSK' s Eastern European market sales by therapy area, 2007
- Figure 4.22: GSK' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.23: Servier' s Eastern European market sales by therapy area, 2007
- Figure 4.24: Servier' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.25: Roche' s Eastern European market sales by therapy area, 2007
- Figure 4.26: Roche' s leading brand sales break-up across the Eastern
European countries, 2007
- Figure 4.27: Zentiva' s Eastern European market sales by therapy area, 2007
- Figure 4.28: Zentiva' s leading brand sales break-up across the Eastern
European countries, 2007
|
有關報告
|
